| abstract |
Disclosed herein are methods of treating cancer utilizing an inhibitor of lysine-specific demethylase 1 (LSDl), an LSDl inhibitor in combination with a DNA damaging agent or an inhibitor of poly (ADP-ribose) polymerase (PARP), or a histone deacetylase (HDAC) inhibitor in combination with a DNA damaging agent or a PARP inhibitor. In one embodiment, the methods include administering a therapeutically effective amount of an LSDl inhibitor to a subject with cancer (such as castration-resistant prostate cancer). In other embodiments, the methods include administering a therapeutically effective amount of an LSDl inhibitor and a therapeutically effective amount of a PARP inhibitor to a subject with cancer (such as prostate cancer, breast cancer, or ovarian cancer). In further embodiments, the disclosed methods include administering a therapeutically effective amount of an HDAC inhibitor and a therapeutically effective amount of a PARP inhibitor to a subject with cancer (such as prostate cancer, breast cancer, or ovarian cancer). |